Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1987-1-22
|
pubmed:abstractText |
Pirmenol, a new class IA antiarrhythmic agent, has shown promise in short-term trials, but long-term efficacy has not been documented. We thus evaluated 11 patients with frequent (greater than or equal to 60/h) premature ventricular complexes (PVC) given oral pirmenol for 25-727 days. Ten of 11 patients entering the long-term open trial had shown greater than or equal to 70% (mean 83%) PVC suppression during in-hospital pirmenol dose ranging. Long-term pirmenol was given in divided doses of 100-600 mg/day. Mean PVC frequency during baseline was 13,078/24 h (range, 3,218-32,718); couplets averaged 481/24 h (1-2,829) and runs 45/24 h (0-334). Ambulatory monitoring was performed at 1, 3, 6, and 12 months, then semiannually. Mean absolute PVC suppression at 1 month averaged 75% (p less than or equal to 0.02). Median individual percentage PVC suppression was 94%. During the first 3 months, 8 patients (73%) continued to show a favorable response (greater than or equal to 70% suppression), and 3 had arrhythmia recurrence and were dropped. One responder was withdrawn after the onset of paroxysmal atrial fibrillation, and another early responder was withdrawn after 3 months because of arrhythmia relapse. Six patients have been treated for over 1 year, with 99% mean PVC suppression. Mean couplet and run frequencies at 1 month decreased by means of 76% (p less than or equal to 0.05) and 92% (p = 0.001) respectively. At 1 year, couplets were suppressed 99.8% and runs by 99.7% in the 6 patients remaining on pirmenol.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
15-22
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3780822-Adult,
pubmed-meshheading:3780822-Aged,
pubmed-meshheading:3780822-Anti-Arrhythmia Agents,
pubmed-meshheading:3780822-Arrhythmias, Cardiac,
pubmed-meshheading:3780822-Electrocardiography,
pubmed-meshheading:3780822-Female,
pubmed-meshheading:3780822-Heart Ventricles,
pubmed-meshheading:3780822-Hemodynamics,
pubmed-meshheading:3780822-Humans,
pubmed-meshheading:3780822-Male,
pubmed-meshheading:3780822-Middle Aged,
pubmed-meshheading:3780822-Outpatients,
pubmed-meshheading:3780822-Piperidines,
pubmed-meshheading:3780822-Time Factors
|
pubmed:year |
1986
|
pubmed:articleTitle |
Initial and long-term outpatient experience with pirmenol for control of ventricular arrhythmias.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|